pathdoc / Shutterstock.com
Intellectual property in the life sciences arena can be an attractive investment target, but a long process of evaluation must take place first, cautions Dimitar Georgiev, founder and CEO of Paralax Life Sciences.
Evaluating an investment in the life sciences sector is essential, as mistakes can be encountered easily.Intellectual property-related investments should be divided into the following categories:
- IP developed from scratch
This is where the real cherry-picking takes place. It’s the cheapest but also the most risky form of investment, where up to 99% of the targets could fail because of a range of reasons. Risks are dependent on the viability of the IP. This is the category with the real thrill.
- IP developed and acquired at an early development stage
This is a form of investment with well-defined risks and benefits, normally preferred by small or medium-sized financial or strategic investors, where the “valley of death” (funding difficulties with the process of translating basic research into a viable product) is fortunately a thing of the past. However, there are still a lot of potential troubles ahead.
Life Sciences Intellectual Property Review (LSIPR) tracks the increasing challenges for intellectual property specialists in the rapidly evolving world of life sciences. From gene patents to stem cell research, we provide the very best news and analysis.
To continue reading this article and to access 4,500+ articles, our digital magazines and special reports published for LSIPR subscribers only then you will need a subscription.
If you are already subscribed please login.
Official LSIPR subscribers include:
Allen & Overy
Arnold & Siedsma
Birch, Stewart, Kolasch & Birch LLP (BSKB)
Carpmaels & Ransford
European Patent Office
George Washington Law School
Kirkland & Ellis International LLP
Marks & Clerk
NiKang Therapeutics Inc.
Powell Gilbert LLP
Procopio, Cory, Hargreaves & Savitch LLP
The United States Patent and Trademark Office (USPTO)
World Intellectual Property Office
Dimitar Georgiev, Paralax Life Sciences, patent, investors, trademark, copyright, IP, economies, software, apps,